Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.

Dean Fennell

doi:10.1158/1078-0432.CCR-07-0536

Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.

Dean Fennell

School of Medicine, Dentistry and Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

91 Citations (Scopus)

Original language	English
Pages (from-to)	5942-5951
Number of pages	10
Journal	Clinical Cancer Research
Volume	13(19)
Issue number	19
DOIs	https://doi.org/10.1158/1078-0432.CCR-07-0536
Publication status	Published - 01 Oct 2007

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.1158/1078-0432.CCR-07-0536

Cite this

@article{4223291f3ebf48388392e8563535b397,

title = "Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.",

author = "Dean Fennell",

year = "2007",

month = oct,

day = "1",

doi = "10.1158/1078-0432.CCR-07-0536",

language = "English",

volume = "13(19)",

pages = "5942--5951",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "19",

}

TY - JOUR

T1 - Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.

AU - Fennell, Dean

PY - 2007/10/1

Y1 - 2007/10/1

UR - https://www.scopus.com/pages/publications/35348874294

U2 - 10.1158/1078-0432.CCR-07-0536

DO - 10.1158/1078-0432.CCR-07-0536

M3 - Article

C2 - 17908991

SN - 1078-0432

VL - 13(19)

SP - 5942

EP - 5951

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 19

ER -

Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this